In 2022, Akero Therapeutics announced that its FGF-21 long-acting analog Efruxifemin (AKR-001) can improve liver fibrosis and prevent disease progression in patients with pre-cirrhosis NASH in phase IIb clinical trials [214]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.